OR21-04 Long-term Efficacy And Safety Of Once-weekly Somatrogon In Pediatric Subjects With Growth Hormone Deficiency: Results From Up To 8 Years Of Somatrogon Treatment

Disclosure: Z. Zadik: None. N. Zelinska: Consulting Fee; Self; Novo Nordisk, Berlin-Chemie, Medtronic, Sanofi-Aventis. Research Investigator; Self; MacroGenics, Novo Nordisk, Pfizer, Inc., Merck, OPKO Health, Ferring Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Parexel, Genexine. Speaker; S...

Descripción completa

Detalles Bibliográficos
Autores principales: Zadik, Zvi, Zelinska, Nataliya, Iotova, Violeta, Skorodok, Yulia, Malievskiy, Oleg A, Mauras, Nelly, Valluri, Srinivas R, Pastrak, Aleksandra, Rosenfeld, Ron G, Taylor, Carrie T, Nijher, Monica, Roland, Carl, Wang, Ronnie, Wajnrajch, Michael P, Cara, Jose F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554866/
http://dx.doi.org/10.1210/jendso/bvad114.1522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554866/
http://dx.doi.org/10.1210/jendso/bvad114.1522

Ejemplares similares